[54 Pages Report] Check for Discount on Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) - Pipeline Review, H1 2016 report by Global Markets Direct. Global Markets Directs, Carcinoembryonic Antigen-Related Cell Adhesion Molecule...
Background: Cancer antigen 15-3 and carcinoembryonic antigen are used in clinical and laboratory diagnosis of metastatic breast cancer. Previous studies have noted conflicting results about the association between carcinoembryonic antigen and cancer antigen 15-3 in metastatic breast cancer. The present study examined serum tumor marker levels of carcinoembryonic antigen and cancer antigen 15-3 among patients with different subtypes of metastatic breast cancer.Methods: In this cross-sectional study, we assessed metastatic breast cancer patients diagnosed between 2005 and 2012 who referred to academic Hospitals affiliated with Mashhad University of Medical Sciences. The patients were selected by systematic randomization sampling. Demographic, clinical, pathological, and therapeutic data were collected from patients hospital records. Statistical analyses were performed by Statistical Package for the Social Sciences version 16.0 software.Results: A total of 298 eligible patients enrolled in the study.
Carcinoembryonic antigen-related cell adhesion molecule 7 is a protein that in humans is encoded by the CEACAM7 gene. ENSG00000007306 GRCh38: Ensembl release 89: ENSG00000280501, ENSG00000007306 - Ensembl, May 2017 "Human PubMed Reference:". Thompson J, Zimmermann W, Nollau P, Neumaier M, Weber-Arden J, Schrewe H, Craig I, Willcocks T (Jan 1995). "CGM2, a member of the carcinoembryonic antigen gene family is down-regulated in colorectal carcinomas". J Biol Chem. 269 (52): 32924-31. PMID 7806520. Thompson J, Seitz M, Chastre E, Ditter M, Aldrian C, Gespach C, Zimmermann W (May 1997). "Down-regulation of carcinoembryonic antigen family member 2 expression is an early event in colorectal tumorigenesis". Cancer Res. 57 (9): 1776-84. PMID 9135022. "Entrez Gene: CEACAM7 carcinoembryonic antigen-related cell adhesion molecule 7". Human CEACAM7 genome location and CEACAM7 gene details page in the UCSC Genome Browser. Douard R, Wind P, Sales JP, et al. (2006). "Long-term prognostic value of detection of ...
Carcinoembryonic antigen-related cell adhesion molecule 8 (CEACAM8) also known as CD66b (Cluster of Differentiation 66b), is a member of the carcinoembryonic antigen (CEA) gene family. Its main function is cell adhesion, cell migration, and pathogen binding. CEACAM8 is expressed exclusively on granulocytes and used as granulocyte marker. Cluster of differentiation GRCh38: Ensembl release 89: ENSG00000124469 - Ensembl, May 2017 "Human PubMed Reference:". "Entrez Gene: CEACAM8 carcinoembryonic antigen-related cell adhesion molecule 8". Khan WN, Frängsmyr L, Teglund S, et al. (1992). "Identification of three new genes and estimation of the size of the carcinoembryonic antigen family". Genomics. 14 (2): 384-90. doi:10.1016/S0888-7543(05)80230-7. PMID 1427854. Oikawa S, Inuzuka C, Kuroki M, et al. (1991). "A specific heterotypic cell adhesion activity between members of carcinoembryonic antigen family, W272 and NCA, is mediated by N-domains". J. Biol. Chem. 266 (13): 7995-8001. PMID 2022629. Berling ...
TY - JOUR. T1 - Identification of a new carcinoembryonic antigen (CEA) family member in human fetal liver - Cloning and sequence determination of pregnancy- specific glycoprotein 7. AU - Khan, Wasif Noor. AU - Hammarström, Sten. PY - 1990/4/16. Y1 - 1990/4/16. N2 - The carcinoembryonic antigen gene family consists of the CEA- and the Pregnancy-Specific Glycoprotein- (PSG) subfamilies. Human fetal liver express several PSGs. Here we report cloning and sequencing of a new PSG subfamily member, PSG7. It is the fifth type of PSG found in fetal liver. PSG7 has the N-A1-A2-B2-C domain arrangement. Unlike other PSGs the N-terminal of PSG7 is unblocked. PSG7 has a cysteine in the C-terminal domain, which may allow dimerization. Variability analysis according to Wu and Kabat reveals that the region in the N-domain corresponding to complementarity determining region 3 of immunoglobulin is different between PSG subfamily members. Many members, including PSG7, contain the RGD sequence in this region. The ...
PubMed comprises more than 30 million citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full-text content from PubMed Central and publisher web sites.
Looking for carcinoembryonic antigen? Find out information about carcinoembryonic antigen. A glycoprotein found in tissues of the fetal gut during the first two trimesters of pregnancy and in the peripheral blood of individuals with some forms of... Explanation of carcinoembryonic antigen
TY - JOUR. T1 - Immunohistochemical detection of carcinoembryonic antigen and P-glycoprotein in small cell lung cancer at diagnosis and relapse, with special reference to the tissue expression of CEA and response to chemotherapy. AU - Ohnoshi, T.. AU - Ueoka, H.. AU - Segawa, Y.. AU - Kiura, Katsuyuki. AU - Tabata, Masahiro. AU - Shibayama, T.. AU - Maeda, T.. AU - Miyatake, M.. AU - Takigawa, N.. AU - Kimura, I.. PY - 1992. Y1 - 1992. N2 - Small cell lung cancer (SCLC) is one of the most sensitive tumors to drug therapy; however, the majority of patients eventually relapse within a few years. Emergence of drug resistance is thought to play a major role in the dismal course of this disease. However, the mechanism of drug resistance in SCLC still remains obscure. Based on the clinical observation that a significant proportion of patients with relapsing tumor show an elevated serum carcinoembryonic antigen (CEA) concentration while serum neuron-specific enolase (NSE) concentration remains normal, ...
The Development of a Radioimmuno-Assay for Carcino-Embryonic Antigen with some Applications. Clinical Evaluation of Cercino-Ernbryonic Antigen, ...
BACKGROUND: Expansions of gene families are predictive for ongoing genetic adaptation to environmental cues. We describe such an expansion of the carcinoembryonic antigen (CEA) gene family in certain bat families. Members of the CEA family in humans and mice are exploited as cellular receptors by a number of pathogens, possibly due to their function in immunity and reproduction. The CEA family is composed of CEA-related cell adhesion molecules (CEACAMs) and secreted pregnancy-specific glycoproteins (PSGs). PSGs are almost exclusively expressed by trophoblast cells at the maternal-fetal interface. The reason why PSGs exist only in a minority of mammals is still unknown. RESULTS: Analysis of the CEA gene family in bats revealed that in certain bat families, belonging to the subgroup Yangochiroptera but not the Yinpterochiroptera subgroup an expansion of the CEA gene family took place, resulting in approximately one hundred CEA family genes in some species of the Vespertilionidae. The majority of ...
The NK killing activity is regulated by activating and inhibitory NK receptors. All of the activating ligands identified so far are either viral or stress-induced proteins. The class I MHC proteins are the ligands for most of the inhibitory NK receptors. However, in the past few years, several receptors have been identified that are able to inhibit NK killing independently of class I MHC recognition. We have previously demonstrated the existence of a novel inhibitory mechanism of NK cell cytotoxicity mediated by the homophilic carcinoembryonic Ag (CEA)-related cell adhesion molecule 1 (CEACAM1) interactions. In this study, we demonstrate that CEACAM1 also interacts heterophilically with the CEA protein. Importantly, we show that these heterophilic interactions of CEA and CEACAM1 inhibit the killing by NK cells. Because CEA is expressed on a wide range of carcinomas and commonly used as tumor marker, these results represent a novel role for the CEA protein enabling the escape of tumor cells from NK
TY - JOUR. T1 - The prognostic significance of preoperative tumor marker (CEA, CA15-3) elevation in breast cancer patients. T2 - data from the Korean Breast Cancer Society Registry. AU - Nam, Sang eun. AU - Lim, Woosung. AU - Jeong, Joon. AU - Lee, Seeyoun. AU - Choi, Jungeun. AU - Park, Heung Kyu. AU - Jung, Yong Sik. AU - Jung, Seung Pil. AU - Bae, Soo Youn. PY - 2019/1/1. Y1 - 2019/1/1. N2 - Purpose: Tumor markers such as carcinoembryonic antigen (CEA) and cancer antigen 15-3 (CA15-3) are widely used for monitoring breast cancer. However, the prognostic efficacy of preoperative elevations of CEA and CA15-3 levels in breast cancer patients remains controversial. Methods: We retrospectively analyzed the clinicopathological parameters of 149,238 patients in the Korean Breast Cancer Society Registry Database who underwent surgery between January 2000 and December 2015. Results: The patients with elevated CA15-3/CEA levels had worse overall survival (OS) than the patients with normal CA15-3/CEA ...
Carcinoembryonic antigen (CEA) is a glycosylphosphatidylinositol (GPI)-cell surface anchored glycoprotein, first identified in tissue extracts from human colon tumors. The CEA family of genes is part of the immunoglobulin superfamily. In humans, the CEA family consists of 29 genes, 18 of which are normally expressed only during fetal development. Therefore, CEA is not detectable in the blood of healthy adults, but CEA expression is observed in many types of cancer ...
Carcinoembryonic antigen (CEA) is a glycosylphosphatidylinositol (GPI)-cell surface anchored glycoprotein, first identified in tissue extracts from human colon tumors. The CEA family of genes is part of the immunoglobulin superfamily. In humans, the CEA family consists of 29 genes, 18 of which are normally expressed only during fetal development. Therefore, CEA is not detectable in the blood of healthy adults, but CEA expression is observed in many types of cancer ...
The latest market report published by Credence Research, Inc. "Global Carcinoembryonic Antigen (CEA) Market - Growth, Share, Opportunities, Competitive Analysis, and Forecast, 2016 - 2023," the carcinoembryonic antigen (CEA) market was valued at USD 1,624.2 Mn in 2015, and is expected to reach USD 2,787.3 Mn by 2023, expanding at a CAGR of 6.4% from 2016 to 2023.. Market Insights. According to Quest Diagnostics, CEA is an oncofetal glycoprotein present in the gastrointestinal tract and body fluids of the embryo and fetus. This antigen is also present in certain adult gastrointestinal cells, including the mucosal cells of the colorectum, and small amounts are present in blood. Market experts suggest that key growth drivers assisting the growth of CEA market comprises high prevalence of cancer, mounting global geriatric population base, high demand for minimally invasive diagnostic procedures in cancer and increasing application of CEA for diagnosis at several stages of cancer. In addition, a few ...
Diagnostic and prognostic value of carcinoembryonic antigen in pancreatic cancer: a systematic review and meta-analysis Qingcai Meng,1–3,* Si Shi,1–3,* Chen Liang,1–3,* Dingkong Liang,1–3 Wenyan Xu,1–3 Shunrong Ji,1–3 Bo Zhang,1–3 Quanxing Ni,1–3 Jin Xu,1–3 Xianjun Yu1–3 1Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, 2Department of Oncology, Shanghai Medical College, 3Pancreatic Cancer Institute, Fudan University, Shanghai, People’s Republic of China *These authors contributed equally to this work Background: Carcinoembryonic antigen (CEA) is one of the most widely used tumor markers and is increased in 30%–60% of patients with pancreatic cancer. Although carbohydrate antigen 19-9 (CA19-9) is the most important serum biomarker in pancreatic cancer, the diagnostic and prognostic value of CEA is gradually being recognized.Materials and methods: The MEDLINE, EMBASE, and Web of Science databases were
... Carcinoembryonic antigen (CEA) is a glycoprotein involved in cell adhesion. It is normally produced during fetal development, but the production of CEA stops before birth.
Carcinoembryonic Antigen Does this test have other names? CEA What is this test? This test measures a protein called carcinoembryonic antigen (CEA) in your blood. This protein is present on some types of cancer cells. CEA is called a tumor marker because it gives information about cancer in your body. This test may help your doctor find out if your cancer treatment is working or if the cancer is returning after treatment. The test can be used with cancers of the colon and rectum, lung, breast, pancreas,...
TY - JOUR. T1 - Identification of HLA-A24 epitope peptides of carcinoembryonic antigen which induce tumor-reactive cytotoxic T lymphocyte. AU - Nukaya, I.. AU - Yasumoto, M.. AU - Iwasaki, T.. AU - Ideno, M.. AU - Sette, A.. AU - Celis, E.. AU - Takesako, K.. AU - Kato, I.. PY - 1999/1/5. Y1 - 1999/1/5. N2 - Carcinoembryonic antigen (CEA), which is expressed in several cancer types, is a potential target for specific immunotherapy. HLA-A24 is the most frequent allele among Japanese and is also frequently present in Asians and Caucasians. We tested CEA-encoded HLA-A24 binding peptides for their capacity to elicit anti-tumor cytotoxic T lymphocytes (CTL) in vitro. For this purpose, we used CD8+ T lymphocytes from peripheral blood mononuclear cells (PBMC) of a healthy donor and autologous peptide-pulsed dendritic cells as antigen-presenting cells. This approach enabled us to identify 2 peptides, QYSWFVNGTF and TYACFVSNL, which were capable of eliciting CTL lines that lysed tumor cells expressing ...
Free Online Library: France - CARCINOEMBRYONIC ANTIGEN. by Mena Report; Business, international Carcinoembryonic antigen CEA (Oncology)
In the present study we describe the establishment and characteristics of a new human tumor cell line (OV-1063) positive for carcinoembryonic antigen (CEA) originating from ovarian metastatic tumor cells. Analysis of the cultured cells during their in vitro adaptation period revealed while the primary culture exhibited a low proportion of CEA-positive cells, this proportion increased with culture passages and eventually more than 90% of the cells in the established line were CEA-positive. Thus, during the period of adaptation to in vitro growth, a selection for CEA-positive cells took place but the amount of CEA secreted per each positive cell seemed to be constant. Several tumor-associated characteristics were found positive on the established OV-1063 cell line. The in vitro growing cell line exhibited an abnormal chromosome pattern with a near-trisomy karyotype for some chromosomes, colony formation in soft agar as well as positive staining with a monoclonal antibody B38.1. Culture supernatants of the
FROM JAMA Oncology. A new study challenges the practice of measuring carcinoembryonic antigen (CEA) in patients with colon cancer prior to surgery, as is currently recommended by some guidelines. Researchers found that the levels do have predictive value about risk of recurrence when tested after surgery, but they challenge its use before. "Consistent with the literature, our data show that postoperative CEA is more informative than preoperative CEA," the study authors wrote. "Emphasis should be placed on postoperative CEA, and in the setting of modern high-quality imaging, we question the utility of measuring preoperative CEA.". The study, which was published online in JAMA Oncology , noted that testing for CEA - a colorectal cancer tumor marker - had more value prior to the current era of imaging because it could indicate the need to widen a search for metastases.. "In the era of high-quality computed tomography (CT), the utility of measuring preoperative CEA is less obvious because an ...
CEA is a tumor-associated antigen abundantly expressed on several cancer types, including those naturally refractory to chemotherapy. The selection and characterization of human anti-CEA single-chain antibody fragments (scFv) is a first step toward the construction of new anticancer monoclonal antibodies designed for optimal blood clearance and tumor penetration. The human MA39 scFv, selected for its ability to recognize a CEA epitope expressed on human colon carcinomas, was first isolated from a large semi-synthetic ETH-2 antibody phage library, panned on human purified CEA protein. Subsequently, by in vitro mutagenesis of a gene encoding for the scFv MA39, a new library was established, and new scFv antibodies with improved affinity towards the CEA cognate epitope were selected and characterized. The scFv MA39 antibody was affinity-maturated by in vitro mutagenesis and the new scFv clone, E8, was isolated, typed for CEA family member recognition and its CEACAM1, 3 and 5 shared epitope characterized
Mouse monoclonal antibody raised against full length recombinant human Carcinoembryonic Antigen (CEA). Recombinant protein corresponding to full length human Carcinoembryonic Antigen. (MAB14723) - Products - Abnova
After last weeks post on therapeutic tumor infiltrating lymphocytes (TILs), we received a bunch of questions from readers.. I dont have time to answer them all in detail individually (sorry!), but it does provide an opportunity to review the evolving landscape and address some of them within the latest article.. It seems to be a good time to take a broader look at T cell manipulation, especially as it pertains to the application of TILs, chimeric antigen receptors (CAR), and T cell receptors (TCR).. Weve certainly come along way since the historic lecture in 1991 pictured right (photo: National Institutes of Health), but theres still some way to go before the full potential of cancer immunotherapy is reached.. ...
Increased serum CEA levels have been detected in persons with primary colorectal cancer and in patients with other malignancies involving the gastrointestinal tract, breast, lung, ovarian, prostatic, liver and pancreatic cancers. Elevated serum CEA levels have also been detected in patients with nonmalignant disease, especially patients who are older or who are smokers. CEA levels are not useful in screening the general population for undetected cancers. However, CEA levels provide important information about patient prognosis, recurrence of tumors after surgical removal, and effectiveness of therapy. ...
A novel magnetic nanoparticle-based electrochemical immunoassay of carcinoembryonic antigen (CEA) was designed as a model using CEA antibody-functionalized magnetic beads [DNA/Fe3O4/ZrO2; Fe3O4 (core)/ZrO2 (shell) nano particles (ZMPs)] as immunosensing probes. To design the immunoassay, the CEA antibody and O-phenylenediamine (OPD) were initially immobilized on a chitosan/nano gold composite membrane on a glassy carbon electrode (GCE/CS-nano Au), which was used for CEA recognition. Then, horseradish peroxidase (HRP)-labeled anti-CEA antibodies (HRP-CEA Ab2) were bound to the surface of the synthesized magnetic ZMP nanoparticles as signal tag. Thus, the sandwich-type immune complex could be formed between secondary antibody (Ab2) modified DNA/ZMPs nanochains tagged by HRP and GCE/CS-nano Au. Unlike conventional nanoparticle-based electrochemical immunoassays, the recognition elements of this immunoassay included both electron mediators and enzyme labels, which obviously simplifies the electrochemical
The global carcinoembryonic antigen (CEA) market is segmented on the basis of application type into ovarian cancer, colorectal cancer, pancreatic cancer, lung cancer, breast cancer, thyroid cancer and other cancers. In base year 2015, colorectal cancer dominated the overall market in terms of revenue. The key factors responsible for growth of CEA market are increase in number of population consuming alcohol, sedentary lifestyle, and high intake of saturated fats in all age groups. Moreover, rising preference for CEA test in cancer diagnosis and management is expected to assist its market growth in the near future.. In base year 2015, North America was observed as the largest CEA market due to high public awareness related to early cancer diagnosis, rising preference for minimally invasive cancer diagnosis tests and sophisticated health care facilities for cancer management. Incessant technological developments followed by new discoveries of specific antigens and biomarkers are anticipated to ...
CEA is a large glycoprotein (~200 kD) consisting of a single polypeptide chain with varying carbohydrate components. Elevated CEA levels can be detected in smokers, patients with colorectal polyps, pancreatitis, liver disease, pulmonary infectious, inflammatory bowel disease and renal failure. Clinically, CEA is used to determine tumor recurrence post-operatively following resection of colon carcinoma.
Tumor markers play an important role in the identification of human malignancies. It has been shown that the carcinoembryonic antigen (CEA, CEACAM5) is a promoter of metastasis in epithelial cancers that is widely used as a clinical marker. The aim of this study is to elucidate the network of genes that are involved in the CEA-induced liver metastasis. Previously, we have shown that CEA is accumulated in the lungs and livers of rats by interacting with their macrophages. We identified and cloned a new gene (CEAR) for the CEA-binding protein, which is located on the surface of fixed liver macrophages, Kupffer cells (Bajenova et al, 2001). It has been shown that the interaction of CEA and CEAR proteins increases the production of IL-1, IL-10, IL-6, TNF-α cytokines (Thomas et al, 2011). This interaction changes the expression of liver adhesion molecules that enhances the survival of cancer cells to the liver. We also suggested that CEA synthesis by cancer cells may influence the E-cadherin adhesion
Carcinoembryonic Antigen (CEA) / CD66 Antibody, Mouse Monoclonal Antibody [Clone SPM584 ] validated in WB, IHC, IF, FC (AH11034-7), Abgent
Carcinoembryonic Antigen (CEA) / CD66 Antibody - Without BSA and Azide, Mouse Monoclonal Antibody [Clone SPM551 ] validated in IHC-P, IF, FC (AH10385-100), Abgent
... , Authors: Dessen P. Published in: Atlas Genet Cytogenet Oncol Haematol.
Carcinoembryonic antigen (CEA) answers are found in the Guide to Diagnostic Tests powered by Unbound Medicine. Available for iPhone, iPad, Android, and Web.
Global carcinoembryonic antigen market value surpassed USD 1.9 billion in 2017 and is expected to witness more than 6.7% CAGR from 2018 to 2024 owing to increasing incidences for cancer disease, especially colorectal cancer.
In this study, a sandwich-type electrochemical (EC) immunosensor was proposed to detect a carcinoembryonic antigen (CEA) based on Au-graphene and [email protected] blue (MB). The Au nanoparticles (NPs)-vertical graphene (VG) electrode efficiently amplifies the response signal by immobilizing a large amount of the c
Definition Carcinoembryonic antigen (CEA) is an antigen (protein) present in very small quantities in adult tissue. A greater than normal amount may be suggestive of cancer. Normally, its values range
This test measures a protein called carcinoembryonic antigen (CEA) in your blood. This protein is present on some types of cancer cells.
This test measures a protein called carcinoembryonic antigen (CEA) in your blood. This protein is present on some types of cancer cells.
This test measures a protein called carcinoembryonic antigen (CEA) in your blood. This protein is present on some types of cancer cells.
This test measures a protein called carcinoembryonic antigen (CEA) in your blood. This protein is present on some types of cancer cells.
This test measures a protein called carcinoembryonic antigen (CEA) in your blood. This protein is present on some types of cancer cells.
Based on previous experiments in nude mice, showing that fluoresceinated monoclonal antibodies against carcinoembryonic antigen localized specifically in human carcinoma xenografts and could be detected by laser-induced fluorescence, we performed a feasibility study to determine whether this immunophotodiagnosis method could be applied in the clinic. Six patients, with known primary colorectal carcinoma, received an i.v. injection of 4.5 or 9 mg of mouse-human chimeric anti-carcinoembryonic antigen monoclonal antibody coupled with 0.10-0.28 mg of fluorescein (molar ratio 1/10 to 1/14). The monoclonal antibody was also labeled with 0.2-0.4 mCi of 125I (1 Ci = 37 GBq). Photodetection of the tumor was done ex vivo on surgically resected tissues for the six patients and in vivo by fluorescence rectosigmoidoscopy for the sixth patient. Upon laser irradiation, clearly detectable heterogeneous green fluorescence from the dye-antibody conjugate was visually observed on all six tumors; almost n
Clone REA428 recognizes an epitope shared by the human CD66a, c, d, and e antigens, which are also known as the human carcinoembryonic antigen (CEA) family. The CEA family has 7 genes belonging to the CEACAM subgroup. These subgroup members are mainly associated with the cell membrane and show a complex expression pattern in normal and cancerous tissues. CD66a (CEACAM1) is an adhesion molecule that is involved in many immune responses associated with infection, inflammation, and cancer. It interacts homophilically with CD66a and heterophilically with CD66e (CEACAM5), but not with other CEACAM proteins. CD66a is expressed on a variety of cells, e.g., some epithelial cells, melanoma, and activated lymphocytes. Within the hematopoietic system, CD66c (CEACAM6) expression is limited to granulocytes and its precursors, where it serves homotypic and heterotypic adhesion and Ca2+ mediated signaling. It is markedly upregulated from intracellular stores after activatio and is also found in epithelia of various
Recombinant human monoclonal antibody raised against human carcinoembryonic antigen (CEA). Original antibody is raised against native purified human CEA. (RAB00036) - Products - Abnova
A carcinoembryonic antigen (CEA) test is used to check how well treatment is working in certain types of cancer, particularly colon cancer.. Carcinoembryonic antigens are harmful substances (usually proteins) that are produced by some types of cancer. In response to the antigens, the body produces antibodies to help fight them.. A CEA test is often carried out after surgery to check carcinoembryonic antigen levels.. As well as being a useful marker in cases of colon cancer, CEA tests can also be used to assess other types of cancer including:. ...
The aim of the present prospective study was to investigate the fluorescence emission of human blood plasma of patients with colorectal cancer.. For years, serum tumor markers have been studied for the diagnosis and follow-up of colorectal cancer, among which carcinoembryonic antigen (CEA) has achieved promising results. However, the sensitivity of CEA for colorectal cancer is less than 25% and elevated CEA levels also occur in patients with benign disease, as well as in patients with other carcinomas. Nevertheless, surveillance programs are often based on the CEA test and combination with other markers is at present a matter of research. Alternative methods based on optical fluoroscopy have been introduced in experimental stages for clinical diagnosis of cancer. Few studies have been reported on the application of native fluorescence spectroscopy of biofluids in the diagnosis of tumoral diseases. The above reported findings prompted us to investigate the fluorescence emission of human blood ...
The aim of the present prospective study was to investigate the fluorescence emission of human blood plasma of patients with colorectal cancer.. For years, serum tumor markers have been studied for the diagnosis and follow-up of colorectal cancer, among which carcinoembryonic antigen (CEA) has achieved promising results. However, the sensitivity of CEA for colorectal cancer is less than 25% and elevated CEA levels also occur in patients with benign disease, as well as in patients with other carcinomas. Nevertheless, surveillance programs are often based on the CEA test and combination with other markers is at present a matter of research. Alternative methods based on optical fluoroscopy have been introduced in experimental stages for clinical diagnosis of cancer. Few studies have been reported on the application of native fluorescence spectroscopy of biofluids in the diagnosis of tumoral diseases. The above reported findings prompted us to investigate the fluorescence emission of human blood ...
Carcinoembryonic antigen (CEA) is a glycoprotein, which was first identified in patients with colonic carcinoma and in epithelial tumours of endodermal origin (gastrointestinal tract) by Gold and Freedman (1). The CEA molecule is quite heterogeneous due to the carbohydrate contents (50-60%) and depending on the purification procedure employed. It is soluble in perchloric acid and has a molecular weight of about 175.000-200.000 Daltons (2). Immunological and genetic characterization of CEA has identified a family of CEA-like molecules sharing common antigenic determinants. The most relevant CEA-like molecule is NCA (non-specific cross-reacting antigen) synthesized both by normal and pathological tissues. The problem of cross-reacting CEA-like molecules when assaying CEA is possible to overcome by the use of monoclonal antibodies. The CanAg CEA EIA is based on two mouse monoclonal antibodies against the Gold epitopes IV and V (3, 4 ...
Blood samples (5 mL) were drawn from the PV and tumor DV and placed in plain tubes. PV blood was obtained 1 hour prior to surgical incision. DV blood was obtained prior to the ligation of any branch of the SMV in patients with proximal colon cancer and prior to ligation of the IMV in patients with distal colon cancers. Samples were immediately centrifuged, and plasma and serum were separately stored at −70°C until analysis. enzyme-linked immunosorbent assay (ELISA) was performed using commercially available kits (IBL-Hamburg GmbH, Hamburg, Germany) according to manufacturers instructions. Diluted serum was transferred to wells of plates pre-coated with primary antibody. Following the recommended incubation period, plates were washed with buffer solution, and substrate solution was added and incubated as instructed. The wells were developed with a color-reagent. Stop solution was added to each well after incubation and the optical density was measured at a wavelength of 450 nm using automated ...